Oyster Point Pharmaceuticals

8/09/2021 11:33:00 PM

Nasal Spray for the Treatment of Dry Eye Syndrome – Attracted USD 120 Million Investment

Oyster is a clinical stage pharmaceutical company focused on the discovery development & commercialization .

Oyster Point Pharmaceuticals-Nasal Spray for Dry Eye Disease

Dry eye syndrome caused by tear film destruction is a common disease experienced by 16 million American adults, but effective treatments other than artificial tears are limited.

In development of a nasal spray that re-establishes natural tear film homeostasis by stimulating glands and cells that produce a natural tear film through activation of the tertiary parasympathetic pathway.

Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma’s lead product candidate, OC-01, a highly selective nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. Dry eye disease is a chronic, progressive condition that impacts more than 30 million Americans and is growing in prevalence.

OC-01’s novel mechanism of action re-establishes tear film homeostasis by activating the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the Lacrimal Functional Unit (LFU).